Ally Bridge Group’s Definium Therapeutics DFTX Stock Holding History

Ally Bridge Group’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.8M	Buy	+400,000	New	+$9.88M	16.64%	1

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ally Bridge Group's DFTX Position: Q4 2025 in Review

Ally Bridge Group sold out of Definium Therapeutics (DFTX) in Q4 2025, closing a stake of 361,444 shares — an estimated $4.26M sold.

Ally Bridge Group first reported a position in DFTX in Q1 2024 and held it in 7 quarters. The position peaked at $9.41M in Q1 2024. 208 funds tracked by Wall St. Rank hold DFTX as of Q4 2025.

Ally Bridge Group reported no remaining Definium Therapeutics position as of Q4 2025 after selling out during the quarter.
Ally Bridge Group sold 361,444 Definium Therapeutics shares in Q4 2025, an estimated $4.26M.
Ally Bridge Group first reported a position in Definium Therapeutics in Q1 2024 and held it in 7 quarters.
Ally Bridge Group's Definium Therapeutics position peaked at $9.41M in Q1 2024.
208 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2025.

Based on Ally Bridge Group's 13F filing for Q4 2025, filed 17 Feb 2026.